Know the news early: the effects and mechanism of venetoclax/venetoclax

Venetoclax (Venetoclax) is a small molecule inhibitor of BCL-2 (B-cell lymphoma-2), used to treat certain patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL) and acute myeloid leukemia (AML).

BCL-2 is a protein that helps determine whether cells live or die. It is called an anti-apoptotic protein because it prevents apoptosis. Apoptosis is the process that leads to cell death. Apoptosis is a process the body uses to get rid of unnecessary or abnormal cells. Venetoclax can restore the apoptotic ability of leukemia cells and promote their death by selectively binding and inhibitingBCL-2 protein. This mechanism could help reduce the burden of leukemia, improve disease progression, and increase patient survival rates. However, it needs to be emphasized that the use of venetoclax should be done under the guidance of a doctor, and some side effects and risks may occur.

The original drug of Venekra has been launched in China and has been included in Class B medical insurance. The price of 100mg*14 tablets per box may be around 2,000 RMB, while the Turkish version of the original drug sold overseas, with the specification of 100mg*112 tablets, costs more than 10,000 RMB per box (the price may fluctuate due to the exchange rate). There are also cheaper generic drugs of Venacla sold overseas. Their pharmaceutical ingredients are basically the same as those of the original drugs sold domestically and abroad. For example, the price of 100mg*120 tablets produced by a Bangladesh pharmaceutical factory is more than 4,000 yuan per box (the price may fluctuate due to the exchange rate).